Rheumatoid Arthritis: Experiments, Evolution, Research Epidemiology and Forecast to 2027

The following research report is a compilation of high-end data that has been researched thoroughly to highlight the various trends prevailing across the Rheumatoid Arthritis market. This study is titled Rheumatoid Arthritis: Epidemiology Forecast to 2027, which carefully examines several vital factors such as market share, market revenue, market dynamics and competitive scenario active in the target market for the period forecast 2027.

Get Sample Copy of This Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2122898

Rheumatoid Arthritis: Epidemiology Forecast to 2027

Summary

Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. Additionally, the condition manifests itself in multiple joints in the body. In RA, the bodys immune system attacks the lining of the joints, known as the synovial membrane, or synovium, causing an inflammatory response. The disease can lead to premature mortality, disability, and decreased quality of life.

GlobalData epidemiologists used sources that provided the diagnosed incidence, diagnosed prevalence, and total prevalence of RA based on the 1987 American College of Rheumatology (ACR) criteria and International Classification of Diseases, Tenth Edition (ICD-10): M05 and M06.

In 2017, the 8MM had 372,519 diagnosed incident cases of RA. This is expected to increase to 412,958 diagnosed incident cases by 2027, at an Annual Growth Rate (AGR) of 1.09%. The increase is driven by the aging population in the 8MM. In 2017, the 8MM had 4,187,350 diagnosed prevalent cases of RA. This is expected to increase to 4,805,959 diagnosed prevalent cases by 2027, at an AGR of 1.48%. In 2017, the 8MM had 5,746,854 total prevalent cases of RA. This is expected to increase to 6,619,425 total prevalent cases by 2027, at an AGR of 1.52%. The US had the highest number of diagnosed incident, diagnosed prevalent cases, and total prevalent cases of RA.

Scope

- The Rheumatoid Arthritis (RA) Epidemiology Report provides an overview of the risk factors and global trends of RA in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Australia).
- This report also includes a 10-year epidemiological forecast for the following segmentations in adults ages 18 years and older across the 8MM: diagnosed incident cases of RA; diagnosed prevalent cases of RA; total prevalent cases of RA (including diagnosed and undiagnosed cases); diagnosed prevalent cases of RA segmented by severity.
- The RA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The RA Epidemiology report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global RA market.
- Quantify patient populations in the global RA market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RA therapeutics in each of the markets covered.
- Understand magnitude of RA cases segmented by severity.

BROWSE Full Report NOW @ https://www.marketresearchhub.com/report/rheumatoid-arthritis-epidemiology-forecast-to-2027-report.html

Table of Contents

1.1 List of Tables
1.2 List of Figures
2 Rheumatoid Arthritis: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Diagnosed Incident Cases of RA
3.4.4 Diagnosed Prevalent Cases of RA
3.4.5 Diagnosed Prevalent Cases of RA by Severity
3.4.6 Total Prevalent Cases of RA
3.5 Epidemiological Forecast for Rheumatoid Arthritis (2017-2027)
3.5.1 Diagnosed Incident Cases of RA
3.5.2 Age-Specific Diagnosed Incident Cases of RA
3.5.3 Sex-Specific Diagnosed Incident Cases of RA
3.5.4 Diagnosed Prevalent Cases of RA
3.5.5 Age-Specific Diagnosed Prevalent Cases of RA
3.5.6 Sex-Specific Diagnosed Prevalent Cases of RA
3.5.7 Diagnosed Prevalent Cases of RA by Severity
3.5.8 Total Prevalent Cases of RA
3.5.9 Age-Specific Total Prevalent Cases of RA
3.5.10 Sex-Specific Total Prevalent Cases of RA
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis

More Information………@@@

About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like pharmaceuticals market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States

Toll Free: 800-998-4852 (US-Canada)
Email: press@marketresearchhub.com

This release was published on openPR.